# Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib

> **NCT04243109** · PHASE2 · TERMINATED · sponsor: **Maimónides Biomedical Research Institute of Córdoba** · enrollment: 6 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Pomalidomide + Cyclophosphamide + Dexamethasone

## Key facts

- **NCT ID:** NCT04243109
- **Lead sponsor:** Maimónides Biomedical Research Institute of Córdoba
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-23
- **Primary completion:** 2019-05-07
- **Final completion:** 2019-05-07
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Low recruitment rate. Lack of interest of the sponsor.
- **Last updated:** 2020-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04243109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04243109, "Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04243109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*